One potential tool in the quest for global eradication of poliomyelitis is a newly developed monovalent type 1 oral poliovirus vaccine. In this study involving 421 infants in Egypt who were given either monovalent type 1 or trivalent vaccine at birth, significantly more infants given the monovalent vaccine underwent seroconversion to type 1 poliovirus (55%, vs. 32% of those given trivalent vaccine). In addition, the monovalent vaccine more effectively reduced shedding of type 1 poliovirus after challenge.

Control of poliovirus in Nigeria has been a considerable challenge, and incomplete control remains a threat to the goal of global eradication of poliomyelitis. The traditional approach to poliovirus control has relied largely on the use of the trivalent oral polio vaccine. Recently the monovalent oral vaccine for serotype 1 has been used to improve protective immunity to this specific serotype. In this case–control study of poliomyelitis in Nigeria, the estimated per-dose efficacies of monovalent and trivalent vaccine for serotype 1 were 67% and 16%, respectively. The estimated efficacy of trivalent vaccine for serotype 3 was 18%.

This large trial of methods used for the evaluation of screening mammograms compared the rate of detection of breast cancer achieved by the use of two readers for each mammogram with that of a single reader using computer-aided detection. The detection rates were virtually the same for both methods, but the recall rate was slightly but significantly higher for mammograms read by a single reader with computer-aided detection than for those read by two readers.

This study shows an association between a broad range of phenotypes and either deletion or duplication of a genomic segment at chromosome 1q21.1, suggesting a fundamental role of the deletion or duplication in early development and challenging the notion that a specific mutation disposes toward a specific disorder or syndrome.